Analytical Data
-
Gene name
MYCN
- Application
-
Alternative Names
MYCN；BHLHE37；NMYC；N-myc proto-oncogene Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04198
-
Expression Region
1-464aa
-
AA Sequence
MPSCSTSTMPGMICKNPDLEFDSLQPCFYPDEDDFYFGGPDSTPPGEDIW KKFELLPTPPLSPSRGFAEHSSEPPSWVTEMLLENELWGSPAEEDAFGLG GLGGLTPNPVILQDCMWSGFSAREKLERAVSEKLQHGRGPPTAGSTAQSP GAGAASPAGRGHGGAAGAGRAGAALPAELAHPAAECVDPAVVFPFPVNKR EPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGRQTSGGDHK ALSTSGEDTLSDSDDEDDEEEDEEEEIDVVTVEKRRSSSNTKAVTTFTIT VRPKNAALGPGRAQSSELILKRCLPIHQQHNYAAPSPYVESEDAPPQKKI KSEASPRPLKSVIPPKAKSLSPRNSDSEDSERRRNHNILERQRRNDLRSS FLTLRDHVPELVKNEKAAKVVILKKATEYVHSLQAEEHQLLLEKEKLQAR QQQLLKKIEHARTC
-
Molecular Weight
77 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The MYCN protein, a member of the MYC oncogene family, is primarily involved in cell proliferation and differentiation. It plays a crucial role in neuroblastoma, a common pediatric cancer characterized by the overexpression of MYCN. Research has shown that MYCN amplification is associated with poor prognosis and aggressive tumor behavior, making it a significant focus in cancer biology. Given its pivotal role in oncogenesis, understanding MYCN's structure and function is essential for developing targeted therapies. The generation of recombinant MYCN protein allows researchers to investigate its biological activities and interactions with other molecular partners in a controlled environment. This approach aids in elucidating the mechanisms through which MYCN drives tumorigenesis and identifies potential therapeutic targets. The study of MYCN recombinants has also led to insights into its role in transcription regulation and cellular signaling pathways, further cementing its status as a key player in cancer research. Therefore, the characterization of MYCN recombinant protein is vital for advancing our understanding of neuroblastoma and ultimately contributing to the development of new therapeutic strategies.
